A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy

被引：0
|
作者：
Nannis, Gabriel N. [1 ]
Griffiths, Elizabeth A. [2 ]
Savona, Michael R. [3 ]
Odenike, Olatoyosi [4 ]
Roboz, Gail J. [5 ]
O'Connell, Casey L. [6 ]
Dillingham, Jacqueline [7 ]
Wason, Prieya [7 ]
Zhu, Lixia [7 ]
Chan, Danna [7 ]
Keer, Harold N. [7 ]
Oganesian, Aram [7 ]
Dao, Kim-Hien [7 ]
DiNardo, Courtney D. [8 ]
机构：
[1] Stanford Univ, Div Hematol, Dept Med, Sch Med, Stanford, CA USA
[2] Roswell Pk Comprehens Canc Ctr, New York, NY USA
[3] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN USA
[4] Univ Chicago, Chicago, IL USA
[5] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
[6] Univ Southern Calif, USC Keck Sch Med, Los Angeles, CA USA
[7] Astex Pharmaceut Inc, Pleasanton, CA USA
[8] Univ Texas MD, Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146264
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1245
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Pratz, Keith
    Cherry, Mohamad
    Altman, Jessica K.
    Cooper, Brenda W.
    Cruz, Jose Carlos
    Jurcic, Joseph G.
    Levis, Mark J.
    Lin, Tara L.
    Perl, Alexander E.
    Podoltsev, Nikolai A.
    Schiller, Gary J.
    Liu, Chaofeng
    Bahceci, Erkut
    BLOOD, 2017, 130
  • [42] Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Pratz, Keith W.
    Cherry, Mohamad
    Altman, Jessica K.
    Cooper, Brenda
    Cruz, Jose Carlos
    Jurcic, Joseph G.
    Levis, Mark J.
    Lin, Tara L.
    Perl, Alexander E.
    Podoltsev, Nikolai A.
    Schiller, Gary J.
    Liu, Chaofeng
    Bahceci, Erkut
    BLOOD, 2018, 132
  • [43] Phase 2, Randomized, Double-Blind, Placebo Controlled Study of Inecaclcitol Combined with Decitabine versus Decitabine: A New Treatment Strategy for Elderly AML Patients Unfit for Intensive Chemotherapy
    Hermine, Olivier
    Dufour-Lamartinie, Jean Francois
    Renaux, Stephanie
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S279 - S279
  • [44] CULMINATE: A phase II study of cusatuzumab plus azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy.
    Trudel, Geralyn Carol
    Howes, Angela J.
    Jeste, Neelum
    Tryon, Jeffrey J.
    Xiu, Liang
    Kane, Colleen
    Nottage, Kerri
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Erba, Harry P.
    Levy, Moshe Y.
    Vasu, Sumithira
    Stein, Anthony S.
    Fathi, Amir T.
    Maris, Michael B.
    Advani, Anjali
    Faderl, Stefan
    Smith, Scott E.
    Wood, Brent L.
    Walter, Roland B.
    Yang, Jay
    Donnellan, William B.
    Feldman, Eric J.
    Voellinger, Jenna L.
    Ravandi, Farhad
    BLOOD, 2016, 128 (22)
  • [46] A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results
    Pratz, Keith W.
    Cherry, Mohamad
    Podoltsev, Nikolai A.
    Altman, Jessica K.
    Perl, Alexander E.
    Cooper, Brenda W.
    Jurcic, Joseph G.
    Lin, Tara L.
    Schiller, Gary J.
    Wu, Ruishan
    Hill, Jason E.
    Gill, Stanley C.
    James, Angela
    Rich, Elizabeth Shima
    Hasabou, Nahla
    Levis, Mark J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S230 - S230
  • [47] VENETOCLAX REAL-WORLD OBSERVATIONAL STUDY ON EFFECTIVENESS AND TREATMENT MANAGEMENT IN PATIENTS WITH NEWLY DIAGNOSED AML WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY IN ITALY - VERO
    Della Porta, M. G.
    Volpicelli, P.
    Caira, M.
    Malgieri, S.
    Nucciarelli, D.
    Gualberti, G.
    Finsinger, P.
    HAEMATOLOGICA, 2024, 109 : 89 - 89
  • [48] Venetoclax Combined with "7+3" Induction Chemotherapy Induces High Rates of MRD-Negative Remission in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Irrespective of Age
    Mantzaris, Loannis
    Goldfinger, Mendel
    Shah, Nishi
    Munoz, Annemarie
    Dhawan, Aradhika
    Chambers, Nicole
    Fehn, Karen
    Victor, Joel
    Shastri, Aditi
    Gritsman, Kira
    Kornblum, Noah
    Sica, Alejandro
    Cooper, Dennis L.
    Verma, Amit
    Kim, Mimi
    Steidl, Ulrich
    Feldman, Eric J.
    Konopleva, Marina Y.
    BLOOD, 2023, 142
  • [49] Intensive Induction Chemotherapy Vs Hypomethylating Agents plus Venetoclax (HMA/VEN) in NPM1-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study
    Bewersdorf, Jan Philipp
    Shimony, Shai
    Shallis, Rory M.
    Liu, Yiwen
    Schaefer, Eva Johanna
    Zeidan, Amer M.
    Goldberg, Aaron D.
    Stein, Eytan M.
    Marcucci, Guido
    Lindsley, Coleman
    Chen, Evan C.
    Ramos, Jorge
    Stein, Anthony Selwyn
    DeAngelo, Daniel J.
    Neuberg, Donna S.
    Stone, Richard M.
    Ball, Brian J.
    Stahl, Maximilian
    BLOOD, 2023, 142
  • [50] Therapy Management and Outcomes in Newly Diagnosed Unfit AML Patients Receiving Venetoclax plus HMA - Insights from a Prospective Real-World Study in Switzerland and Austria
    Pabst, Thomas
    Lehmann, Thomas
    Pichler, Petra
    Machherndl-Spandl, Sigrid
    Gregor, Michael
    Goede, Jeroen S.
    Gerull, Sabine
    Mayer, Daniel Maria
    Lambert, Jean-Francois
    Germanier, Catherine
    Stuessi, Georg
    BLOOD, 2024, 144 : 2413 - 2414
12345